Benjamin Hohl Sells 6,018 Shares of Enliven Therapeutics (NASDAQ:ELVN) Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl sold 6,018 shares of the stock in a transaction dated Friday, July 17th. The shares were sold at an average price of $52.64, for a total value of $316,787.52. Following the completion of the transaction, the chief financial officer owned 46,054 shares of the company’s stock, valued at $2,424,282.56. This represents a 11.56% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Benjamin Hohl also recently made the following trade(s):

• On Wednesday, June 17th, Benjamin Hohl sold 6,018 shares of Enliven Therapeutics stock. The stock was sold at an average price of $43.80, for a total value of $263,588.40.

Enliven Therapeutics Trading Down 1.5%

NASDAQ:ELVN opened at $52.97 on Thursday. The stock’s 50-day moving average is $46.25 and its 200-day moving average is $38.17. Enliven Therapeutics, Inc. has a 1-year low of $14.78 and a 1-year high of $55.79. The stock has a market cap of $3.23 billion, a P/E ratio of -31.72 and a beta of 0.24.

Enliven Therapeutics (NASDAQ:ELVN) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.06. As a group, equities analysts forecast that Enliven Therapeutics, Inc. will post -1.57 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Enliven Therapeutics by 8.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,729 shares of the company’s stock valued at $428,000 after purchasing an additional 1,693 shares during the last quarter. Goldman Sachs Group Inc. boosted its position in Enliven Therapeutics by 61.3% during the first quarter. Goldman Sachs Group Inc. now owns 211,752 shares of the company’s stock valued at $4,167,000 after acquiring an additional 80,506 shares during the last quarter. Jane Street Group LLC acquired a new stake in Enliven Therapeutics during the 1st quarter worth about $578,000. Legal & General Group Plc raised its position in shares of Enliven Therapeutics by 52.2% in the 2nd quarter. Legal & General Group Plc now owns 32,225 shares of the company’s stock worth $646,000 after acquiring an additional 11,058 shares in the last quarter. Finally, Quantbot Technologies LP lifted its stake in shares of Enliven Therapeutics by 47.1% in the 2nd quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock valued at $90,000 after purchasing an additional 1,434 shares during the period. Institutional investors and hedge funds own 95.08% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on ELVN shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enliven Therapeutics in a report on Friday, July 17th. Stifel Nicolaus increased their price objective on Enliven Therapeutics from $60.00 to $80.00 and gave the company a “buy” rating in a report on Wednesday, July 1st. Guggenheim began coverage on Enliven Therapeutics in a research report on Tuesday, May 12th. They set a “buy” rating and a $80.00 target price for the company. JonesTrading lifted their target price on Enliven Therapeutics from $45.00 to $70.00 and gave the stock a “buy” rating in a report on Monday, June 29th. Finally, The Goldman Sachs Group upped their price target on Enliven Therapeutics from $59.00 to $67.00 and gave the company a “buy” rating in a research report on Tuesday, July 21st. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $70.50.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.